Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Nuvation Bio Inc. (NUVB) reports results ...

Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...

For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital ...

Climb Bio Inc (NASDAQ:CLYM) is one of the best performing small cap stocks so far in 2026. Oppenheimer lifted the price ...

That morning, Belite announced that its leading drug candidate, tinlarebant, met its primary endpoint in a phase 3 trial. The medicine was being tested to determine its efficacy in treating ...

On February 17, 2026, Knoll Capital Management disclosed a purchase of 473,591 shares of Nuvation Bio (NYSE:NUVB), an estimated $2.93 million trade based on quarterly average pricing. Nuvation Bio is ...

Have you looked into how Bio-Rad Laboratories (BIO) performed internationally during the quarter ending March 2026? Considering the widespread global presence of this maker of instruments used in ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today ...

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG) (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of ...